UBS analyst Alex Kramm raised the firm’s price target on Cushman & Wakefield to $12 from $9 and keeps a Neutral rating on the shares. The firm says the recovery is “intact,” with Q2 likely just a minor “blip,” the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CWK:
- Cushman & Wakefield Announces Board Resignation and New Appointments
- Cushman & Wakefield chairman Brett White to retire, Steve Plavin to succeed
- CBRE Group price target raised to $170 from $160 at Morgan Stanley
- Cushman & Wakefield price target raised to $14.50 from $14 at Morgan Stanley
- Cushman & Wakefield Shareholders Approve Key Proposals